Featured Products
Welcome
At Amneal we are committed to forming deep relationships with our customers and business partners as well as creating strong value throughout the supply chain. That’s why we've created this website. Get to know Amneal, as a company, partner, supplier, employer or customer. At amneal.com we provide valuable information about our operations, leaders, products, business principles and more… as well as details on how to get in touch with us.
Welcome to Amneal Pharmaceuticals—generic’s new generation. We encourage you to learn more about our remarkable company. Explore our site.
News and Press
AMNEAL RECEIVES FDA APPROVAL FOR TRAMADOL/APAP TABLETS
Amneal Pharmaceuticals is pleased to announce that it received U.S. FDA approval to manufacture combination Tramadol HCl in 37.5 mg strength and Acetaminophen in 325 mg strength (Tramadol/APAP) in tablet form effective December 9, 2009.
More »
Amneal Pharmaceuticals is pleased to announce that it received U.S. FDA approval to manufacture combination Tramadol HCl in 37.5 mg strength and Acetaminophen in 325 mg strength (Tramadol/APAP) in tablet form effective December 9, 2009.
More »
AMNEAL EXPANDS GENERIC PORTFOLIO WITH LAUNCH OF ALPRAZOLAM ER AND BENAZEPRIL HCI TABLETS
Amneal Pharmaceuticals is pleased to announce the availability of its Alprazolam Extended Release Tablets in strengths of 0.5 mg, 1 mg, 2 mg and 3 mg.
More »
Amneal Pharmaceuticals is pleased to announce the availability of its Alprazolam Extended Release Tablets in strengths of 0.5 mg, 1 mg, 2 mg and 3 mg.
More »
AMNEAL RECEIVES FDA APPROVAL FOR NIZATIDINE ORAL SOLUTION, THE FIRST
GENERIC ORAL SOLUTION FOR AXID® IN THE MARKET
Amneal Pharmaceuticals is pleased to announce that it has received U.S. FDA approval to manufacture Nizatidine Oral Solution in the 15 mg/mL strength effective November 18, 2009.
More »
Amneal Pharmaceuticals is pleased to announce that it has received U.S. FDA approval to manufacture Nizatidine Oral Solution in the 15 mg/mL strength effective November 18, 2009.
More »